A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 105 participants.

Also called NCT06845202

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06845202
  • EU CT 2024-519005-35-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Canada, Chile, Germany, Poland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06845202. Randomized; triple masking; primary purpose treatment. Start 2025-03-03 (actual); primary completion 2027-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Condition
Obese or Overweight Healthy Volunteers
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
ALN-4324
Intervention (Drug)
Placebo
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06845202
Content hash
de06973b6a1fc846ea2ad74f465428c63a63b841be49d0323c26b2a924fb11ad